Sudeep Pharma to Host Q1FY27 Earnings Call with Analysts on August 5
NiveshIQ
NSE: SUDEEPPHRM · Healthcare
Sudeep Pharma Ltd.
₹879.15▲ ₹17.35 (+2.01%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SUDEEPPHRM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Sudeep Pharma Ltd.
Sudeep Pharma Limited is a leading manufacturer and seller of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries. The company generates revenue primarily from the sale of mineral salts, calcium carbonate, and micronutrient premixes to various health-focused applications. Its products are used in functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. Sudeep Pharma has expanded its presence in the United States, Europe, United Kingdom, and Latin America. The company's recent addition to the S&P Global BMI Index is a testament to its growing global recognition. With a 27.9% year-over-year revenue growth in FY26 to ₹642.3 crore, Sudeep Pharma is poised for continued growth. An
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹454.67 Cr +6.70% | ₹497.41 Cr +9.40% | ₹642.26 Cr +29.10% |
| EBITDA Margin | 41.11% | 39.82% | 39.00% |
| Net Profit | ₹133.19 Cr +113.70% | ₹138.69 Cr +4.10% | ₹174.28 Cr +25.70% |
| EPS | ₹11.79 | ₹12.28 | ₹15.50 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Sudeep Pharma Q1 Results: Earnings call scheduled for Aug 5
Pharma sector stocks gain today, July 27: Sudeep Pharma jumps 4.77%, Lupin rises 2.45%, Torrent Pharma up 1.39%
🔒
+ 3 more stories about Sudeep Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹182 Cr, PAT ₹49 Cr, EPS ₹4.38, EBITDA margin 37.9%. Growth context: revenue YoY -60.1%, PAT YoY -99.0%, revenue QoQ +5.8%, PAT QoQ +2.3%. Street verdict: inline, revenue surprise -1.0%, PAT surprise +2.2%.
Recent corporate activity highlights geographic expansion and international growth as the primary near-term growth lever...
FY26 (last completed FY): revenue ₹642 Cr, PAT ₹174 Cr, EBITDA margin 39.0%, EPS ₹15.50. Year-on-year: revenue YoY +29.1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SUDEEPPHRM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SUDEEPPHRM alongside your other holdings
Unlock full SUDEEPPHRM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Sudeep Pharma Ltd.?
NiveshIQ detects active intelligence signals for Sudeep Pharma Ltd. (SUDEEPPHRM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Sudeep Pharma Ltd.?
Sudeep Pharma Ltd. operates in the Healthcare sector with a market capitalisation of ₹745,460.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.